Imaging of Prostate Cancer Using Fluciclovine

Bital Savir-Baruch; Lucia Zanoni; David M Schuster

doi:10.1016/j.ucl.2018.03.015

Imaging of Prostate Cancer Using Fluciclovine

Urol Clin North Am. 2018 Aug;45(3):489-502. doi: 10.1016/j.ucl.2018.03.015. Epub 2018 Jun 15.

Authors

Bital Savir-Baruch¹, Lucia Zanoni², David M Schuster³

Affiliations

¹ Department of Radiology, Loyola University Medical Center, 2160 South 1st Avenue, Maywood, IL 60153, USA. Electronic address: biatl.savir-baruch@lumc.edu.
² Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, via Massarenti 9, Bologna 40138, Italy.
³ Department of Radiology and Imaging Sciences, Emory University Hospital, Emory University, 1364 Clifton Road, Atlanta, GA 30322, USA.

PMID: 30031468
DOI: 10.1016/j.ucl.2018.03.015

Abstract

Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States. Despite high prevalence, diagnosis and surveillance is limited due to indolent biology. Functional imaging techniques improved the ability to detect disease. Amino acids are building blocks of proteins and intracellular transport is upregulated in prostate cancer. Normal biodistribution patterns of fluciclovine include uptake in the liver and pancreas with minimal to no urine excretion, a distinct advantage for prostate cancer imaging. This review provides a detailed overview of the use of F-18 fluciclovine PET in prostate cancer imaging.

Keywords: Axumin; CT; FACBC; Fluciclovine; PET; Prostate.

Publication types

Review

MeSH terms

Carboxylic Acids*
Cyclobutanes*
Humans
Male
Positron-Emission Tomography
Prostatic Neoplasms / diagnostic imaging*
Sensitivity and Specificity
Tomography, X-Ray Computed

Substances

Carboxylic Acids
Cyclobutanes
fluciclovine F-18